Neurovascular Intervention Devices Global Market – Forecast To 2024

Publishing Date : May, 2018
Report Code : HCMD0159
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Neurovascular Intervention devices are used treat intracranial aneurysm, ischemic stroke, arteriovenous malformation, carotid stenosis and other diseases like intracranial stenosis, dural fistula, etc. According to IQ4I analysis, the Neurovascular Intervention devices global market is expected to grow at a high single digit CAGR to reach $4,473.2 million by 2024. The increase in incidence and prevalence of neurovascular diseases like intracranial aneurysm, stroke and arteriovenous malformations, increase in aging population, technological advancement, acquisitions and favourable reimbursements are increasing the use of artificial embolization devices, stents, thromobectomy devices and support devices which include microcatheters, embolic protection system and others as an efficient way for treating the neurovascular diseases.

Neurovascular Intervention devices global market is segmented on the basis of products, applications and geography. The products are segmented into artificial embolization devices, stents, thrombectomy devices and support devices. The artificial embolization devices segment accounted the largest share in 2017 and is projected to grow at mid single digit CAGR from 2017 to 2024 due to technological advancements in coils & flow diverter, development of coils for dual application i.e. for intracranial aneurysm and arteriovenous malformation. The artificial embolization devices are sub-segment into coils, liquid embolics, flow diverter and flow disruptor. The coil segment accounted the largest share in 2017 due to development of softest coils and more number of companies producing bare metal coils over coated coils due to its advantages. The liquid embolics segment is fastest growing segment and is projected to grow at a strong CAGR of 8.7% from 2017 to 2024 due to its advantages like presence of effective embolic materials which penetrates small vessels, cohesiveness and non-adherence when compared to glues. The coils are further classified into bare metal coils and coated coils. The bare metal coil segment accounted for the largest share in 2017 and fastest growing segment and is projected to grow at a CAGR of 6.4% from 2017 to 2024 due to increased compatibility, efficacy and cost efficient. The Stents are sub-segmented into intracranial stents and carotid stents. The carotid stents segment accounted the largest share of 74.2% and fastest growing segment in 2017 due to development of self expanding stents. The intracranial stents are sub-segmented into stenosis stent, aneurysm coil stent, neck reconstruction stent and stent graft. The aneurysm coil stents segment accounted the largest share in 2017 and fastest growing segment during forecasting period due to increase intracranial aneurysm procedures. The thrombectomy devices are sub-segmented into stent retrievers and aspiration devices. The stent retriever segment accounted the largest share of 76.3% and fastest growing segment from 2017 to 2024 due to product approvals and expansion in indication of treatment from 6 hrs to 24 hrs. The Support devices are sub-segmented into microcatheters, embolic protection system and others. The microcatheter segment accounted the largest share in 2017.

The applications are segmented into intracranial aneurysm, ischemic stroke, arteriovenous malformation and carotid stenosis & others. Among application, intracranial aneurysm segment accounted for the largest share in 2017 due to the increase in incidence and prevalence of intracranial aneurysm and increase in aging population. The Ischemic stroke segment is fastest growing segment during forecasting period due to increase in product regulatory approvals of thrombectomy devices, increase in ischemic stroke patients and procedures, technological advancement in stent retriever and aspiration devices.

Geography is segmented as North America (U.S. and others), Europe (Germany, U.K., France and Others), Asia-Pacific (Japan, China, India, and Others) and Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the highest market share followed by Europe. Favourable reimbursement coverage and increase in incidence and prevalence of neurovascular diseases are the driving factors of Neurovascular Intervention devices market. However, Asian countries especially India and China are the fastest growing nations at strong CAGR of 11.4% from 2017 to 2024 with its growing demand for neurovascular intervention device due to increase in aging population and decreasing the cost of neurovascular products.

The Neurovascular Intervention devices market is a consolidated, highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the Neurovascular Intervention device are Stryker Corporation (U.S.), Medtronic Plc (Ireland), Terumo Corporation (Japan), Balt Extrusion (Blockade Medical, LLC) (France), Penumbra, Inc. (U.S.), Johnson & Johnson (U.S.), Acandis GmbH (Germany), Microport Scientific Corporation (China), Phenox GmbH (Germany), Penumbra Inc (U.S.), Abbott Laboratories (U.S.), InspireMD (Israel), Boston Scientific Corporation (U.S.) and Cardinal Health (Cordis Corporation) (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

• North America

o U.S.

o Others

• Europe

o Germany

o U.K.

o France

o Others

• Asia-Pacific

o Japan

o China

o India

o Others

• Rest of the World (RoW)

o Brazil

o Rest of Latin America

o Middle East & Others

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASE IN INCIDENCE AND PREVALENCE OF NEUROVASCULAR DISEASES
        • 3.3.1.2     INCREASE IN AGEING POPULATION
        • 3.3.1.3     TECHNOLOGICAL ADVANCEMENTS IN MINIMALLY INVASIVE PRODUCTS
        • 3.3.1.4     FAVORABLE REIMBURSEMENT POLICIES
        • 3.3.1.5     ACQUISITIONS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     ADVERSE EVENTS AND COMPLICATIONS WITH THE IMPLANTATIONS OF NEUROVASCULAR INTERVENTION DEVICES
        • 3.3.2.2     LACK OF SKILLED AND TRAINED PROFESSIONALS
        • 3.3.2.3     PRODUCT RECALLS
        • 3.3.2.4     STRINGENT REGULATORY POLICES
        • 3.3.2.5     AVAILABILITY OF ALTERNATIVE PRODUCTS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13485 MEDICAL DEVICES
        • 3.4.1.3     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     EUROPE
      • 3.4.5     JAPAN
      • 3.4.6     CHINA
      • 3.4.7     INDIA
    • 3.5     REIMBURSEMENT SCENARIO
      • 3.5.1     REIMBURSEMENT TABLE
    • 3.6     CLINICAL TRIALS
    • 3.7     PATENT TRENDS
    • 3.8     TECHNOLOGICAL ADVANCEMENTS
      • 3.8.1     INTRODUCTION
      • 3.8.2     INTEGRATED BALLOON SYSTEM
      • 3.8.3     SOFT COIL TECHNOLOGY
      • 3.8.4     ADUJSTABLE CLOT RETREIVER
      • 3.8.5     ADVANCEMENTS IN FLOW DIVERTER
    • 3.9     PRODUCT APPROVALS
    • 3.10     PORTER’S FIVE FORCE ANALYSIS
      • 3.10.1     THREAT OF NEW ENTRANTS
      • 3.10.2     THREAT OF SUBSTITUTES
      • 3.10.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.10.4     BARGAINING POWER OF SUPPLIERS
      • 3.10.5     BARGAINING POWER OF BUYERS
    • 3.11     SUPPLY CHAIN ANALYSIS
    • 3.12     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.12.1     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE ANALYSIS
      • 3.12.2     COILS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.3     FLOW DIVERTERS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.4     INTRACRANIAL STENT GLOBAL MARKET SHARE ANALYSIS
      • 3.12.5     CAROTID STENT GLOBAL MARKET SHARE ANALYSIS
      • 3.12.6     STENT RETRIEVER GLOBAL MARKET SHARE ANALYSIS
    • 3.13     NEUROVASCULAR INTERVENTION DEVICES NUMBER OF UNITS BY REGION
      • 3.13.1     COILS NUMBER OF UNITS BY REGION
      • 3.13.2     LIQUID EMBOLICS NUMBER OF UNITS BY REGION
      • 3.13.3     STENT RETRIEVER NUMBER OF UNITS BY REGION
      • 3.13.4     CAROTID STENT NUMBER OF UNITS BY REGION
    • 3.14     NEUROVASCULAR INTERVENTION DEVICES COMPANY COMPARISON TABLE BY CLASSIFICATION, PRODUCTS AND APPLICATIONS
    • 3.15     MARKET PENETRATION OF NEUROVASCULAR INTERVENTION DEVICE MARKET
  • 4     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     ARTIFICIAL EMBOLIZATION DEVICES
      • 4.2.1     COILS
        • 4.2.1.1     BARE METAL COILS
        • 4.2.1.2     COATED COILS
      • 4.2.2     LIQUID EMBOLICS
      • 4.2.3     FLOW DIVERTERS
      • 4.2.4     FLOW DISRUPTOR
    • 4.3     STENTS
      • 4.3.1     INTRACRANIAL STENTS
        • 4.3.1.1     STENOSIS STENTS
        • 4.3.1.2     ANEURYSM COIL STENTS
        • 4.3.1.3     NECK RECONSTRUCTION STENTS
        • 4.3.1.4     STENT GRAFT
      • 4.3.2     CAROTID STENTS
    • 4.4     THROMBECTOMY DEVICES
      • 4.4.1     STENT RETRIEVERS
      • 4.4.2     ASPIRATION DEVICES
    • 4.5     SUPPORT DEVICES
      • 4.5.1     MICROCATHETERS
      • 4.5.2     EMBOLIC PROTECTION SYSTEM
      • 4.5.3     OTHERS
  • 5     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     INTRACRANIAL ANEURYSM
    • 5.3     ISCHEMIC STROKE
    • 5.4     ARTERIOVENOUS MALFORMATION
    • 5.5     CAROTID STENOSIS AND OTHERS
  • 6     REGIONAL ANALYSIS
    • 6.1     INTRODUCTION
    • 6.2     North America
      • 6.2.1     U.S.
      • 6.2.2     OTHERS
    • 6.3     EUROPE
      • 6.3.1     GERMANY
      • 6.3.2     U.K.
      • 6.3.3     FRANCE
      • 6.3.4     OTHERS
    • 6.4     APAC
      • 6.4.1     JAPAN
      • 6.4.2     CHINA
      • 6.4.3     INDIA
      • 6.4.4     OTHERS
    • 6.5     ROW
      • 6.5.1     BRAZIL
      • 6.5.2     REST OF LATIN AMERICA
      • 6.5.3     MIDDLE EAST AND OTHERS
  • 7     COMPETITIVE LANDSCAPE
    • 7.1     INTRODUCTION
    • 7.2     AGREEMENT
    • 7.3     APPROVALS
    • 7.4     ACQUISITIONS
    • 7.5     NEW PRODUCT LAUNCH
    • 7.6     OTHER DEVELOPMENTS
  • 8     MAJOR COMPANIES
    • 8.1     ABBOTT LABORATORIES
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     ACANDIS GMBH
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     BALT EXTRUSION
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     BOSTON SCIENTIFIC CORPORATION
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     CARDINAL HEALTH INC. (CORDIS CORPORATION)
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     PRODUCT PORTFOLIO
      • 8.5.4     KEY DEVELOPMENTS
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     INSPIREMD, INC.
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     PRODUCT PORTFOLIO
      • 8.6.4     KEY DEVELOPMENTS
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     JOHNSON & JOHNSON
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     MEDTRONIC, PLC
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     MICROPORT SCIENTIFIC CORPORATION
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.10     PENUMBRA, INC
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS
    • 8.11     PHENOX GMBH
      • 8.11.1     OVERVIEW
      • 8.11.2     FINANCIALS
      • 8.11.3     PRODUCT PORTFOLIO
      • 8.11.4     KEY DEVELOPMENTS
      • 8.11.5     BUSINESS STRATEGY
      • 8.11.6     SWOT ANALYSIS
    • 8.12     STRYKER CORPORATION
      • 8.12.1     OVERVIEW
      • 8.12.2     FINANCIALS
      • 8.12.3     PRODUCT PORTFOLIO
      • 8.12.4     KEY DEVELOPMENTS
      • 8.12.5     BUSINESS STRATEGY
      • 8.12.6     SWOT ANALYSIS
    • 8.13     TERUMO CORPORATION
      • 8.13.1     OVERVIEW
      • 8.13.2     FINANCIALS
      • 8.13.3     PRODUCT PORTFOLIO
      • 8.13.4     KEY DEVELOPMENTS
      • 8.13.5     BUSINESS STRATEGY
      • 8.13.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 2     COILS NUMBER OF UNITS, BY REGION, (2016-2024) (NO’S)
      • TABLE 3     LIQUID EMBOLICS NUMBER OF UNITS, BY REGION, (2016-2024) (NO’S)
      • TABLE 4     STENT RETRIEVER NUMBER OF UNITS, BY REGION, (2016-2024) (NO’S)
      • TABLE 5     CAROTID STENT NUMBER OF UNITS, BY REGION,(2016-2024) (NO’S)
      • TABLE 6     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT, (2016-2024) ($MN)
      • TABLE 7     ARTIFICIAL EMBOLIZATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 8     ARTIFICIAL EMBOLIZATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 9     COILS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 10     COILS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 11     BARE METAL COILS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 12     COATED COILS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 13     LIQUID EMBOLICS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 14     FLOW DIVERTERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 15     FLOW DISRUPTOR GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 16     STENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 17     STENTS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 18     INTRACRANIAL STENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 19     INTRACRANIAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 20     STENOSIS STENTS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 21     ANEURYSM COIL STENTS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 22     NECK RECONSTRUCTION STENTS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 23     STENT GRAFT GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 24     CAROTID STENTS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 25     THROMBECTOMY DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 26     THROMBECTOMY DEVICES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 27     STENT RETRIEVERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 28     ASPIRATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 29     SUPPORT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 30     SUPPORT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 31     MICROCATHETERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 32     EMBOLIC PROTECTION SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 33     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 34     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 35     INTRACRANIAL ANEURYSM GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 36     ISCHEMIC STROKE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 37     ARTERIOVENOUS MALFORMATION GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 38     CAROTID STENOSIS & OTHERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 39     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 40     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2016-2024) ($MN)
      • TABLE 41     NORTH AMERICA ARTIFICIAL EMBOLIZATION DEVICE MARKET, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 42     NORTH AMERICA COILS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 43     NORTH AMERICA STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 44     NORTH AMERICA INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 45     NORTH AMERICA THROMBECTOMY DEVICE MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 46     NORTH AMERICA SUPPORT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 47     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 48     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 49     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2016-2024) ($MN)
      • TABLE 50     EUROPE ARTIFICIAL EMBOLIZATION DEVICE MARKET, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 51     EUROPE COILS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 52     EUROPE STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 53     EUROPE INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 54     EUROPE THROMBECTOMY DEVICE MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 55     EUROPE SUPPORT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 56     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 57     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 58     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2016-2024) ($MN)
      • TABLE 59     APAC ARTIFICIAL EMBOLIZATION DEVICE MARKET, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 60     APAC COILS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 61     APAC STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 62     APAC INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 63     APAC THROMBECTOMY DEVICE MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 64     APAC SUPPORT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 65     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 66     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 67     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2016-2024) ($MN)
      • TABLE 68     ROW ARTIFICIAL EMBOLIZATION DEVICE MARKET, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 69     ROW COILS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 70     ROW STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 71     ROW INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 72     ROW THROMBECTOMY DEVICE MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 73     ROW SUPPORT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2016-2024) ($MN)
      • TABLE 74     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 75     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 76     AGREEMENT (2016 - 2018)
      • TABLE 77     APPROVALS (2016 - 2018)
      • TABLE 78     ACQUISITIONS (2016 - 2018)
      • TABLE 79     NEW PRODUCT LAUNCH (2016 - 2018)
      • TABLE 80     OTHER DEVELOPMENTS (2016 - 2018)
      • TABLE 81     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 82     ABBOTT LABORATORIES: TOTAL REVENUE BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 83     ABBOTT LABORATORIES: TOTAL REVENUE BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 84     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 85     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 86     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 87     CARDINAL HEALTH INC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 88     CARDINAL HEALTH INC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 89     CARDINAL HEALTH INC: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 90     INSPIREMD, INC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 91     INSPIREMD: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 92     INSPIREMD, INC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 93     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 94     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 95     JOHNSON & JOHNSON: TOTAL REVENUE, BY MEDICAL DEVICES SEGMENTS, (2015-2017) ($MN)
      • TABLE 96     JOHNSON & JOHNSON: TOTAL REVENUE, BY ORTHOPAEDICS SEGMENTS, (2015-2017) ($MN)
      • TABLE 97     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 98     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 99     MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 100     MEDTRONIC, PLC: RESTORATIVE THERAPIES GROUP TOTAL REVENUE, BY SUB-SEGMENTS, (2015-2017) ($MN)
      • TABLE 101     MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 102     MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 103     MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 104     MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 105     PENUMBRA, INC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 106     PENUMBRA, INC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 107     PENUMBRA, INC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 108     STRYKER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 109     STRYKER CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 110     STRYKER CORPORATION: TOTAL REVENUE, BY NEUROTECHNOLOGY AND SPINE SUB-SEGMENT, (2014-2016) ($MN)
      • TABLE 111     STRYKER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 112     TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 113     TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 114     TERUMO CORPORATION CARDIAC & VASCULAR BUSINESS: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 115     TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET
      • FIGURE 3     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2012–2017)
      • FIGURE 9     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 (%)
      • FIGURE 12     COILS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 (%)
      • FIGURE 13     FLOW DIVERTERS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 (%)
      • FIGURE 14     INTRACRANIAL STENT GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 (%)
      • FIGURE 15     CAROTID STENT GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 (%)
      • FIGURE 16     STENT RETRIEVER MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 (%)
      • FIGURE 17     COIL NUMBER OF UNITS, BY REGION (2017 V/S 2024) (NO’S)
      • FIGURE 18     LIQUID EMBOLICS NUMBER OF UNITS, BY REGION (2017 V/S 2024) (NO’S)
      • FIGURE 19     STENT RETREIVER NUMBER OF UNITS, BY REGION (2017 V/S 2024) (NO’S)
      • FIGURE 20     CAROTID STENT NUMBER OF UNITS, BY REGION (2017 V/S 2024) (NO’S)
      • FIGURE 21     NEUROVASCULAR INTERVENTION DEVICE U.S. MARKET PENETRATION, BY APPLICATION (2017) (%)
      • FIGURE 22     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT (2017 V/S 2024) ($MN)
      • FIGURE 23     ARTIFICIAL EMBOLIZATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2017) ($MN)
      • FIGURE 24     ARTIFICIAL EMBOLIZATION DEVICES GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 25     COILS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 26     COILS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 27     BARE METAL COILS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 28     COATED COILS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 29     LIQUID EMBOLICS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 30     FLOW DIVERTERS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 31     FLOW DISRUPTOR GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 32     STENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2017 V/S 2024) ($MN)
      • FIGURE 33     STENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2017) ($MN)
      • FIGURE 34     STENTS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 35     INTRACRANIAL STENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2017 V/S 2024) ($MN)
      • FIGURE 36     INTRACRANIAL STENTS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 37     STENOSIS STENTS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 38     ANEURYSM COIL STENTS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 39     NECK RECONSTRUCTION STENTS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 40     STENT GRAFT GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 41     CAROTID STENTS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 42     THROMBECTOMY DEVICES GLOBAL MARKET REVENUE, BY TYPE (2017 V/S 2024) ($MN)
      • FIGURE 43     THROMBECTOMY DEVICES GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 44     STENT RETRIEVERS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 45     ASPIRATION DEVICES GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 46     SUPPORT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2017 V/S 2024) ($MN)
      • FIGURE 47     SUPPORT DEVICES GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 48     MICROCATHETERS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 49     EMBOLIC PROTECTION SYSTEM GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 50     OTHERS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 51     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 52     INTRACRANIAL ANEURYSM GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 53     ISCHEMIC STROKE GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 54     ARTERIOVENOUS MALFORMATION GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 55     CAROTID STENOSIS & OTHERS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 56     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN), CAGR (%)
      • FIGURE 57     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY PRODUCT & APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 58     NORTH AMERICA ARTFICIAL EMBOLIZATION DEVICES & STENT MARKET SHARE, BY PRODUCT TYPE, (2017 V/S 2024) (%)
      • FIGURE 59     NORTH AMERICA THROMBECTOMY DEVICES & SUPPORT DEVICES MARKET SHARE, BY PRODUCT TYPE, (2017 V/S 2024) (%)
      • FIGURE 60     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE, BY COUNTRY, (2017 V/S 2024) (%)
      • FIGURE 61     U.S. NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 62     OTHERS NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 63     EUROPE NEUROVASCULAR INTERVENTION DEVICES SHARE, BY PRODUCT & APPLICATION (2017 V/S 2024) (%)
      • FIGURE 64     EUROPE ARTIFICIAL EMBOLIZATION DEVICE & STENT MARKET SHARE, BY PRODUCT TYPE, (2017 V/S 2024) (%)
      • FIGURE 65     EUROPE THROMBECTOMY DEVICE & SUPPORT DEVICE MARKET SHARE, BY PRODUCT TYPE MARKET, (2017 V/S 2024) (%)
      • FIGURE 66     EUROPE NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY COUNTRY, (2017 V/S 2024) ($MN)
      • FIGURE 67     GERMANY NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 68     U.K. NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 69     FRANCE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 70     OTHERS NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 71     APAC NEUROVASCULAR INTERVENTION DEVICES SHARE, BY PRODUCT & APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 72     APAC ARTIFICIAL EMBOLIZATION DEVICE & STENT MARKET SHARE, BY PRODUCT TYPE, (2017 V/S 2024) (%)
      • FIGURE 73     APAC THOMBECTOMY DEVICE & SUPPORT DEVICE MARKET SHARE, BY PRODUCT TYPE, (2017 V/S 2024) (%)
      • FIGURE 74     APAC NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE, BY COUNTRY, (2017 V/S 2024) (%)
      • FIGURE 75     JAPAN NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 76     CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 77     INDIA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 78     OTHERS NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 79     ROW NEUROVASCULAR INTERVENTION DEVICES SHARE, BY PRODUCT & APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 80     ROW ARTIFICIAL EMBOLIZATON DEVICE & STENT MARKETSHARE, BY PRODUCT TYPE, (2017 V/S 2024) (%)
      • FIGURE 81     ROW THROMBECTOMY DEVICE DEVICES & SUPPORT DEVICE MARKET SHARE, BY PRODUCT TYPE, (2017 V/S 2024) (%)
      • FIGURE 82     ROW NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE, BY COUNTRY, (2017 V/S 2024) (%)
      • FIGURE 83     BRAZIL NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 84     REST OF LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 85     MIDDLE EAST AND OTHERS NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 86     KEY GROWTH STRATEGIES, (2016-2018)
      • FIGURE 87     SWOT: ABBOTT LABORATORIES
      • FIGURE 88     SWOT: ACANDIS GMBH
      • FIGURE 89     SWOT: BALT EXTRUSION
      • FIGURE 90     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 91     SWOT: CARDINAL HEALTH INC
      • FIGURE 92     SWOT: INSPIREMD, INC
      • FIGURE 93     SWOT: JOHNSON & JOHNSON
      • FIGURE 94     SWOT: MEDTRONIC, PLC
      • FIGURE 95     SWOT: MICROPORT SCIENTIFIC CORPORATION
      • FIGURE 96     SWOT: PENUMBRA, INC
      • FIGURE 97     SWOT: PHENOX GMBH
      • FIGURE 98     SWOT: STRYKER CORPORATION
      • FIGURE 99     SWOT: TERUMO CORPORATION

      LIST OF COMPANIES

      • 1     ABBOTT LABORATORIES
      • 2     ACANDIS GMBH
      • 3     ACHIEVA MEDICAL
      • 4     ALLIUM MEDICAL
      • 5     ASAHI INTECC CO., LTD.
      • 6     BALT EXTRUSION
      • 7     BALTON SP. Z O.O.
      • 8     BOSTON SCIENTIFIC CORPORATION
      • 9     CARDIATIS
      • 10     CARDINAL HEALTH INC
      • 11     CONTEGO MEDICAL, LLC
      • 12     EVASC MEDICAL SYSTEMS
      • 13     INSPIRE MD
      • 14     JOHNSON & JOHNSON
      • 15     MEDTRONIC PLC
      • 16     MERLIN MD PTE. LTD.
      • 17     MICROPORT SCIENTIFIC CORPORATION
      • 18     NEXGEN MEDICAL SYSTEMS, INC
      • 19     OXFORD ENDOVASCULAR LTD
      • 20     PENUMBRA INC
      • 21     PERFLOW MEDICAL LTD
      • 22     PHENOX GMBH
      • 23     RAPID MEDICAL
      • 24     SILK ROAD MEDICAL INC
      • 25     STRYKER CORPORATION
      • 26     TERUMO CORPORATION
      • 27     W. L. GORE & ASSOCIATES, INC